Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients

14 Jun 2017

Abstract excerpt

// Takashi Takeshita 1 , Yutaka Yamamoto 1 , Mutsuko Yamamoto-Ibusuki 2 , Mai Tomiguchi 1 , Aiko Sueta 1 , Keiichi Murakami 1 , Yoko Omoto 1,3 and Hirotaka Iwase 1 1 Department of Breast and Endocrine Surgery, Graduate School of Medical Science, Kumamoto University, Honjo, Chuo-Ku, Kumamoto, Japan 2 Department of Molecular-Targeting Therapy for Breast Cancer, Kumamoto University Hospital, Honjo, Chuo-Ku,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer Genomics and Diagnostics
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28881720
DOI: 10.18632/oncotarget.18479

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patientsPMID 28881720Read ↗

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancerSemantic proximity Read ↗

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.Semantic proximity Read ↗

Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.Semantic proximity Read ↗

ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.Semantic proximity Read ↗

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.Semantic proximity Read ↗

High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy.Semantic proximity Read ↗

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.Semantic proximity Read ↗

Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.Semantic proximity Read ↗

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer PatientsSemantic proximity Read ↗

Molecular Profiling of Endocrine Resistance in HR+/HER2-Metastatic Breast Cancer: Insights from Extracellular Vesicles-Derived DNA and ctDNA in Liquid Biopsies.Semantic proximity Read ↗

Coupling multiplex pre-amplification and droplet digital PCR for longitudinal monitoring of <i>ESR1</i> and <i>PIK3CA</i> mutations from plasma cell-free DNASemantic proximity Read ↗

Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.